Slogan 2020 short v3.png
 
pic01.png

ABOUT US​

LifeMax is a privately held, clinical stage biotech company focused on developing first-in-class or best-in-class therapeutics for orphan diseases that have few or no options. Our lead program, LM-030, is ready to enter into a pivotal trial for the treatment of Netherton syndrome.

May 5, 2020 
LifeMax Appoints Michael Huang, MD, as Chief Medical Officer

Redwood City, California – (Business Wire) – May 05, 2020 – LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on developing first-in-class or best-in-class ...

April 14, 2020
LifeMax Receives Fast Track Designation For LM-030 for the Treatment ...

Redwood City, California – (Business Wire) – April 14, 2020 – LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on developing first-in-class or best-in-class ...

March 30, 2020 
LifeMax Launches AmMax Bio Following The License Of Worldwide Rights...

Redwood City, California – (Business Wire) – March 30, 2020 – LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on treating orphan diseases that have few or no therapeutic ...

NEWS

article02.jpg

R&D

Through in-licensing from or collaboration with big pharma/biotech companies and/or academic institutions, we have established a robust and science-driven portfolio that targets the underlying causes of the various orphan diseases with few or no approved options. Our focus is on first-in-class or best-in-class therapeutics that will truly bring meaningful and/or life-saving benefits to patients. We are also leveraging sponsored collaboration and research with universities to help de-risk potential projects before their adoption into our pipeline.

Slogan 2020 short v3.png